A review of the current evidence for maintenance therapy in ovarian cancer

被引:16
作者
Foster, Talia [1 ]
Brown, T. Michelle [1 ]
Chang, Jane [1 ]
Menssen, Hans D. [1 ]
Blieden, Marissa B. [1 ]
Herzog, Thomas J. [1 ]
机构
[1] Columbia Univ, Med Ctr, New York, NY 10027 USA
关键词
Ovarian cancer; Maintenance therapy; Review; Economics; Quality of life; Systematic review; SOUTHWEST-ONCOLOGY-GROUP; III RANDOMIZED-TRIAL; QUALITY-OF-LIFE; PLATINUM-BASED CHEMOTHERAPY; CLINICAL COMPLETE REMISSION; COST-EFFECTIVENESS ANALYSIS; STAGE-IV OVARIAN; CONSOLIDATION THERAPY; PHASE-III; INTRAPERITONEAL CISPLATIN;
D O I
10.1016/j.ygyno.2009.07.026
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives. Ovarian cancer (OC) typically is diagnosed at advanced stages, in which the primary goal of therapy is to prolong progression-free survival (PFS) and overall survival (OS). In recent years, maintenance therapy has been tested for this purpose in advanced OC (AOC). Literature on maintenance therapy in AOC was systematically reviewed to assess current knowledge regarding the impact of this therapeutic approach. Methods. A MEDLINE search was performed 2/2009 for articles published 1/2001-1/2009 pertaining to OC maintenance therapy guidelines, patterns, and outcomes. A second search used keywords specific to maintenance and included primary studies published in the last 10 years. Of 406 sources identified, 36 primary studies and 16 review articles were included in this systematic review. A third search used the keyword "consolidation" to find maintenance articles not identified through other searches; of 48 additional sources, 13 primary studies and 6 reviews were included. A fourth search of non-MEDLINE-indexed sources yielded 14 additional relevant publications from the same time period. Results. Among practice guidelines identified, only the National Comprehensive Cancer Network (NCCN) 2008 guidelines provide recommendations regarding maintenance therapy, assigning it a category 2B recommendation. No studies were identified that reported Current treatment patterns or economic outcomes in maintenance therapy: quality of life data were reported in one study. A variety of agents have been tested for maintenance, with paclitaxel the most commonly evaluated. The Southwest Oncology Group-Gynecologic Oncology Group 178 trial has found that 12 cycles of paclitaxel extend PFS (by 7 months) compared to 3 months paclitaxel, but Could not adequately evaluate OS. Conclusions. Maintenance therapy may improve clinical Outcomes in AOC, but additional research is needed to demonstrate an OS advantage. Future studies should investigate the long-term clinical benefit of maintenance treatment and its impact on resource utilization and health-related quality of life. (C) 2009 Published by Elsevier Inc.
引用
收藏
页码:290 / 301
页数:12
相关论文
共 106 条
[1]   Randomized trial of adjuvant intraperitoneal alpha-interferon in stage III ovarian cancer patients who have no evidence of disease after primary surgery and chemotherapy: An intergroup study [J].
Alberts, DS ;
Hannigan, EV ;
Liu, PY ;
Jiang, C ;
Wilczynski, S ;
Copeland, L ;
Markman, M .
GYNECOLOGIC ONCOLOGY, 2006, 100 (01) :133-138
[2]   Long-term follow-up of a phase II trial of oral altretamine for consolidation of clinical complete remission in women with stage III epithelial ovarian cancer in the Southwest Oncology Group [J].
Alberts, DS ;
Jiang, C ;
Liu, PY ;
Wilczynski, S ;
Markman, M ;
Rothenberg, ML .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2004, 14 (02) :224-228
[3]  
Aletti GD, 2007, MAYO CLIN PROC, V82, P751
[4]  
*AM CANC SOC, 2008, OV CANC DET GUID
[5]  
American Cancer Society, 2008, CANC FACTS FIGS
[6]   Intraperitoneal cisplatin and paclitaxel in ovarian cancer [J].
Armstrong, DK ;
Bundy, B ;
Wenzel, L ;
Huang, HQ ;
Baergen, R ;
Lele, S ;
Copeland, LJ ;
Walker, JL ;
Burger, RA .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (01) :34-43
[7]   Radiation therapy and biological compounds for consolidation therapy in advanced ovarian cancer [J].
Auranen, A. ;
Grenman, S. .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2008, 18 :44-46
[8]  
Awada A, 2004, EUR J GYNAECOL ONCOL, V25, P673
[9]   Stage III and IV ovarian cancer in the South West of England: five-year outcome analysis for cases treated in 1998 [J].
Bailey, J ;
Murdoch, J ;
Anderson, R ;
Weeks, J ;
Foy, C .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2006, 16 :25-29
[10]   Clinical trial endpoints in ovarian cancer: Report of an FDA/ASCO/AACR public workshop [J].
Bast, Robert C. ;
Thigpen, J. Tate ;
Arbuck, Susan G. ;
Basen-Engquist, Karen ;
Burke, Laurie B. ;
Freedman, Ralph ;
Horning, Sandra J. ;
Ozols, Robert ;
Rustin, Gordon J. ;
Spriggs, David ;
Wenzel, Lari B. ;
Pazdur, Richard .
GYNECOLOGIC ONCOLOGY, 2007, 107 (02) :173-176